Search Results - "Harrington, Kimberly H."

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia by Reusch, Uwe, Harrington, Kimberly H, Gudgeon, Chelsea J, Fucek, Ivica, Ellwanger, Kristina, Weichel, Michael, Knackmuss, Stefan H J, Zhukovsky, Eugene A, Fox, Judith A, Kunkel, Lori A, Guenot, Jeanmarie, Walter, Roland B

“…Randomized studies with gemtuzumab ozogamicin have validated CD33 as a target for antigen-specific immunotherapy of acute myelogenous leukemia (AML). Here, we…”
Get full text

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330 by Laszlo, George S, Beddoe, Mary E, Godwin, Colin D, Bates, Olivia M, Gudgeon, Chelsea J, Harrington, Kimberly H, Walter, Roland B

Get full text

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk by Harrington, Kimberly H, Gudgeon, Chelsea J, Laszlo, George S, Newhall, Kathryn J, Sinclair, Angus M, Frankel, Stanley R, Kischel, Roman, Chen, Guang, Walter, Roland B

“…The CD33/CD3-bispecific T-cell engaging (BiTE) antibody construct, AMG 330, potently lyses CD33+ leukemic cells in vitro. Using specimens from 41 patients with…”
Get full text

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin by Rosen, David B, Harrington, Kimberly H, Cordeiro, James A, Leung, Ling Y, Putta, Santosh, Lacayo, Norman, Laszlo, George S, Gudgeon, Chelsea J, Hogge, Donna E, Hawtin, Rachael E, Cesano, Alessandra, Walter, Roland B

“…Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a…”
Get full text

Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: A report from the children's oncology group by Walter, Roland B., Laszlo, George S., Alonzo, Todd A., Gerbing, Robert B., Levy, Shawn, Fitzgibbon, Matthew P., Gudgeon, Chelsea J., Ries, Rhonda E., Harrington, Kimberly H., Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S., W. McIntosh, Martin, Meshinchi, Soheil

“…Acute myeloid leukemia (AML) encompasses a heterogeneous group of diseases, and novel biomarkers for risk refinement and stratification are needed to optimize…”
Get full text

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML by Kung Sutherland, May S., Walter, Roland B., Jeffrey, Scott C., Burke, Patrick J., Yu, Changpu, Kostner, Heather, Stone, Ivan, Ryan, Maureen C., Sussman, Django, Lyon, Robert P., Zeng, Weiping, Harrington, Kimberly H., Klussman, Kerry, Westendorf, Lori, Meyer, David, Bernstein, Irwin D., Senter, Peter D., Benjamin, Dennis R., Drachman, Jonathan G., McEarchern, Julie A.

“…Outcomes in acute myeloid leukemia (AML) remain unsatisfactory, and novel treatments are urgently needed. One strategy explores antibodies and their drug…”
Get full text

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group by Laszlo, George S, Alonzo, Todd A, Gudgeon, Chelsea J, Harrington, Kimberly H, Kentsis, Alex, Gerbing, Robert B, Wang, Yi-Cheng, Ries, Rhonda E, Raimondi, Susana C, Hirsch, Betsy A, Gamis, Alan S, Meshinchi, Soheil, Walter, Roland B

“…The original article [1] contains an omission of information in the Financial support sub-section of the Declarations section. The authors would like to…”
Get full text

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML by Laszlo, George S., Gudgeon, Chelsea J., Harrington, Kimberly H., Dell'Aringa, Justine, Newhall, Kathryn J., Means, Gary D., Sinclair, Angus M., Kischel, Roman, Frankel, Stanley R., Walter, Roland B.

“…CD33 is a valid target for acute myeloid leukemia (AML) but has proven challenging for antibody-drug conjugates. Herein, we investigated the cellular…”
Get full text

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia by Laszlo, George S, Harrington, Kimberly H, Gudgeon, Chelsea J, Beddoe, Mary E, Fitzgibbon, Matthew P, Ries, Rhonda E, Lamba, Jatinder K, McIntosh, Martin W, Meshinchi, Soheil, Walter, Roland B

“…With the demonstration of improved survival of some acute myeloid leukemia (AML) patients with the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO),…”
Get full text

Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group by Laszlo, George S, Alonzo, Todd A, Gudgeon, Chelsea J, Harrington, Kimberly H, Gerbing, Robert B, Wang, Yi-Cheng, Ries, Rhonda E, Raimondi, Susana C, Hirsch, Betsy A, Gamis, Alan S, Meshinchi, Soheil, Walter, Roland B

“…Exploratory gene expression array analyses suggested multimerin-1 (MMRN1) to be a predictive biomarker in acute myelogenous leukemia (AML). Following up on…”
Get full text

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group by Laszlo, George S, Alonzo, Todd A, Gudgeon, Chelsea J, Harrington, Kimberly H, Kentsis, Alex, Gerbing, Robert B, Wang, Yi-Cheng, Ries, Rhonda E, Raimondi, Susana C, Hirsch, Betsy A, Gamis, Alan S, Meshinchi, Soheil, Walter, Roland B

“…Recent studies have identified myocyte enhancer factor 2C (MEF2C) as cooperating oncogene in acute myeloid leukemia (AML) and suggested a contribution to the…”
Get full text

High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group by Laszlo, George S., Ries, Rhonda E., Gudgeon, Chelsea J., Harrington, Kimberly H., Alonzo, Todd A., Gerbing, Robert B., Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S., Meshinchi, Soheil, Walter, Roland B.

“…Abstract Deregulated cytokine signaling is a characteristic feature of acute myeloid leukemia (AML), and expression signatures of cytokines and chemokines have…”
Get full text

High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group by Gudgeon, Chelsea J., Harrington, Kimberly H., Laszlo, George S., Alonzo, Todd A., Gerbing, Robert B., Gamis, Alan S., Raimondi, Susana C., Hirsch, Betsy A., Meshinchi, Soheil, Walter, Roland B.

Get full text

Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML) by Reusch, Uwe, Harrington, Kimberly H., Gudgeon, Chelsea J., Fucek, Ivica, Ellwanger, Kristina, Weichel, Michael, Knackmuss, Stefan, Zhukovsky, Eugene, Fox, Judith A., Guenot, Jeanmarie, Walter, Roland B.

“…Abstract only…”
Get full text

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk by Harrington, Kimberly H., Gudgeon, Chelsea J., Laszlo, George S., Newhall, Kathryn J., Sinclair, Angus M., Frankel, Stanley R., Kischel, Roman, Chen, Guang, Walter, Roland B.

“…Background: Recent studies have demonstrated that AMG 330, a novel CD33/CD3-directed bispecific T-cell engaging (BiTE¨) antibody, is highly active against…”
Get full text

High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group by Laszlo, George S., Alonzo, Todd A., Gudgeon, Chelsea J., Harrington, Kimberly H., Kentsis, Alex, Gerbing, Robert B., Wang, Yi-Cheng, Ries, Rhonda E., Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S., Meshinchi, Soheil, Walter, Roland B.

“…Background: Myocyte enhancer factor 2C (MEF2C) was initially identified as essential transcription factor for cardiac muscle development. However, subsequent…”
Get full text

Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Children’s Oncology Group by Laszlo, George S., Alonzo, Todd A., Gudgeon, Chelsea J., Harrington, Kimberly H., Gerbing, Robert B., Wang, Yi-Cheng, Ries, Rhonda E., Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S., Meshinchi, Soheil, Walter, Roland B.

“…Background: Both cytogenetic and molecular abnormalities have been identified in acute myeloid leukemia (AML) that provide the framework for diagnostic…”
Get full text

Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia by Laszlo, George S., Lionberger, Jack M., Harrington, Kimberly H., Gudgeon, Chelsea J., Othus, Megan, Appelbaum, Frederick R., Bernstein, Irwin D., Walter, Roland B.

“…The cellular origin of human acute myeloid leukemia (AML) remains controversial. Limited G6PD-based X chromosome inactivation (XCI) studies suggested…”
Get full text

Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia by Walter, R B, Laszlo, G S, Lionberger, J M, Pollard, J A, Harrington, K H, Gudgeon, C J, Othus, M, Rafii, S, Meshinchi, S, Appelbaum, F R, Bernstein, I D

“…Recent technological advances led to an appreciation of the genetic complexity of human acute myeloid leukemia (AML), but underlying progenitor cells remain…”
Get full text

Sequential Acquisition of Somatic Mutations In Progenitors with Differential Proliferative Potential In Human Acute Myeloid Leukemia by Pollard, Jessica A., Meshinchi, Soheil, Harrington, Kimberly H., Zeng, Rong, Bernstein, Irwin D., Walter, Roland B.

“…Abstract 755 Evidence suggests that leukemic transformation is a multistep process in acute myeloid leukemia (AML). However, the cell of origin for human…”
Get full text